A Body-Care Butter That Isn't for Sale Shows How Biotech Actives Move Between Categories

Core Biogenesis and the Italian ingredient distributor Faravelli have unveiled Skin Longevity Butter, a body-care formulation concept built around two proprietary growth-factor actives, Peauvita and Peauforia. It is not a retail product. It is a demonstration formula, the kind ingredient suppliers hand to brand labs as a template for what their raw materials can become once someone else turns them into a SKU.

That distinction matters more than the product itself. Skin Longevity Butter is the third entry in the Core Biogenesis and Faravelli "Longevity Concepts" collection, following Lip Longevity Gloss and Eye Longevity Shadow. The same pair of actives has now been walked from face serums into lip color, eye color, and body care in successive showcases. That is a platform being stretched across categories through a distributor's demo pipeline, and it is the more interesting story than any single butter formula.

The actives themselves come from Core Biogenesis's Core Bioprocess platform, which grows recombinant epidermal growth factor and fibroblast growth factor-2 inside Camelina sativa seeds and binds them to oleosomes, the lipid-storage particles plants use to hold oil, for stability and delivery. The Strasbourg-founded company, backed by a $10.5 million Series A led by XAnge in 2022, has marketed the pairing on a claim of visible anti-aging results, including reduced wrinkles and improved firmness and brightness, within 14 days. Earlier this year the platform won L'Oréal's Big Bang Beauty Tech Innovation Challenge in the Future Science and Sustainability category, awarded by deputy chief executive Barbara Lavernos, giving the actives a validation point beyond Core Biogenesis's own marketing.

Faravelli's part in this is instructive for anyone trying to read how ingredient innovation actually reaches a shelf. Founded in Milan in 1926 as a raw-materials trading house, the family-owned company has supplied food, pharma and cosmetic ingredients for a century, with a cosmetics division dating to the early 1990s. It does not manufacture actives. It builds formulas around a supplier's chemistry and pitches them to brand clients across its distribution network in Italy, Germany, the Czech Republic, Slovakia, Hungary, Spain, China and the United States. Skin Longevity Butter is that mechanism in miniature: an active-ingredient developer supplying the chemistry, a century-old distributor supplying the formulation showcase and the sales channel into brands that will never touch Core Biogenesis directly.

The category logic behind the launch is the more consequential piece. Body care has spent years playing catch-up to facial skincare's technical vocabulary and formulation depth, and "longevity" is now the term doing the work that "anti-aging" used to do, reframing the pitch from erasing visible signs of aging toward a cellular, healthy-aging story borrowed from the wellness and supplement world. Trade coverage around In-Cosmetics Global's 2026 edition has repeatedly flagged biotech-grown actives as the dominant new-ingredient theme, and this launch is one data point inside that shift rather than a standalone innovation. What Core Biogenesis and Faravelli are testing, in effect, is whether a body-care buyer will pay for the same biotech story that has already sold in serums.

That test is not without friction. Growth factors like EGF and FGF are active on cell-signaling pathways that are also implicated in some cancer biology, which is why EGF-inhibiting drugs exist as a cancer treatment class. In the European Union, cosmetic-grade EGF and FGF are regulated as standard ingredients under the EU Cosmetic Products Regulation, requiring INCI naming, a safety dossier and substantiation for any claims made, and the industry's working assumption is that topical, oleosome-encapsulated growth factors act locally rather than entering systemic circulation. Whether that framing holds up as growth-factor actives spread from niche serums into mass-market body butters is the kind of question that tends to surface once a technology moves from a single premium category into several at once.

For now, Skin Longevity Butter stays a lab demonstration, not a product a shopper can buy. Its purpose is to sit in a formulator's hands as proof that Peauvita and Peauforia work in a heavier, richer base than the serums and gels the actives were designed for. Whether a brand picks it up and turns it into an actual body butter, and whether the growth-factor language sells outside a dermatologist's office, is the next chapter in a rollout that has now touched eyes, lips and skin.